[1]
|
N. Cimerman, P. M. Brguljan, M. Krasovec, S. Suskovic and J. Kos, “Circadian Characteristics of Cathepsins B, H, L, and Stefins A and B, Potential Markers for Disease, in Normal Sera,” Clinica Chimica Acta, Vol. 282, No. 1-2, 1999, pp. 211-218. doi:10.1016/S0009-8981(99)00008-X
|
[2]
|
N. Cimerman, P. M. Brguljan, M. Krasovec, S. Suskovic and J. Kos, “Twenty-Four Hour Variations of Cystatin C and Total Cysteine Proteinase Inhibitory Activity in Sera from Healthy Subjects,” Clinica Chimica Acta, Vol. 291, No. 1, 2000, pp. 89-95.
doi:10.1016/S0009-8981(99)00196-5
|
[3]
|
N. G. Cloven, A. Kyshtoobayeva, R. A. Burger, I. R. Yu and J. P. Fruehauf, “In Vitro Chemoresistance and Biomarker proWles Are Unique for Histologic Subtypes of Epithelial Ovarian Cancer,” Gynecologic Oncology, Vol. 92, No. 1, 2004, pp. 160-166.
doi:10.1016/j.ygyno.2003.09.030
|
[4]
|
D. Gabrijelcic, B. Svetic, D. Spaic, J. Skrk, M. Budihna, I. Dolenc, T. Popovic, V. Cotic and V. Turk, “Cathepsins B, H and L in Human Breast Carcinoma,” European Journal of Clinical Chemistry and Clinical Biochemistry, Vol. 30, No. 2, 1992, pp. 69-74.
|
[5]
|
L. Herszenyi, M. Plebani, P. Carraro, et al., “The Role of Cysteine and Serine Proteases in Colorectal Carcinoma,” Cancer, Vol. 86, No. 7, 1999, pp. 1135-1142.
doi:10.1002/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2
|
[6]
|
J. E. Koblinski, M. Ahram and B. F. Sloane, “Unraveling the Role of Proteases in Cancer,” Clinica Chimica Acta, Vol. 291, No. 2, pp. 113-135.
doi:10.1016/S0009-8981(99)00224-7
|
[7]
|
V. B. Astler and F. A. Coller, “The Prognostic Significance of Direct Extension of Carcinoma of the Colon and Rectum,” Annals of Surgery, Vol. 139, No. 6, 1954, pp. 846-852. doi:10.1097/00000658-195406000-00015
|
[8]
|
R. Castino, D. Pace, M. Demoz, M. Gargiulo, C. Ariatta, E. Raiteri and C. Isidoro, “Lysosomal Proteases as Potential Targets for the Induction of Apoptotic Cell Death in Human Neuroblastomas,” International Journal of Cancer, Vol. 97, No. 6, 2002, pp. 775-779.
doi:10.1002/ijc.10139
|
[9]
|
J. L. Cox, “Cystatins and Cancer,” Frontiers in Bioscience, Vol. 14, 2009, pp. 463-474. doi:10.2741/3255
|
[10]
|
E. Campo, J. Munoz, R. Miquel, A. Palacin, A. Cardesa, B. F. Sloane and M. Emmert-Buck, “Cathepsin B Expression in Colorectal Carcinomas Correlates with Progression and Shortened Patient Survival,” American Journal of Pathology, Vol. 145, No. 2, 1994, pp. 301-309.
|
[11]
|
J. Lankelma, D. Voorend, T. Barwari, J. Koetsveld, A. Van der Spek, A. De Porto, G. Van Rooijen and C. Van Noorden, “Cathepsin L, Target in Cancer Treatment?” Life Sciences, Vol. 86, No. 7-8, 2010, pp. 225-233.
doi:10.1016/j.lfs.2009.11.016
|
[12]
|
L. Hazen, F. Bleeker, B. Lauritzen, J. Song, A. Jonker, B. Van Driel, et al., “Comparative Localization of Cathepsin B Protein and Activity in Colorectal Cancer,” Journal of Histochemistry & Cytochemistry, Vol. 48, No. 10, 2000, pp. 1421-1430. doi:10.1177/002215540004801012
|
[13]
|
L. Herszenyi, M. Plebani, P. Carraro, M. De Paoli, G. Roveroni, R Cardin, et al., “The Role of Cysteine and serine Proteases in Colorectal Carcinoma,” Cancer, Vol. 86, No. 7, 1999, pp. 1135-1142.
doi:10.1002/(SICI)1097-0142(19991001)86:7<1135::AID-CNCR6>3.0.CO;2-2
|
[14]
|
A. M. Troy, K. Sheahan, H. E. Mulcahy, M. J. Duffy, J. M. Hyland and D. P. O’Donoughe, “Expression of Cathepsin B and L Antigen and Activity Is Associated with Early Colorectal Progression,” European Journal of Cancer, Vol. 40, No. 10, 2004, pp. 1610-1616.
doi:10.1016/j.ejca.2004.03.011
|
[15]
|
F. Farinati, L. Herszenyi, M. Plebani, P. Carraro, R. Cardin, M. De Paoli, G. Roveroni, M. Rugge, D. Nitti and R. Naccarato, “Increased Levels of Cathepsin B and L, Urokinase-Type Plasminogen Activator and Inhibitor Type-1 as an Early Event in Gastric Carcinogenesis,” Carcinogenesis, Vol. 17, No. 12, 1996, pp. 2581-2587.
doi:10.1093/carcin/17.12.2581
|
[16]
|
M. Talieri, S. Papadopoulou, A. Scorilas, D. Xynopoulos, N. Arnogianaki, G. Plataniotis, J. Yotis and N. Agnanti, “Cathepsin B and Cathepsin D Expression in the Progression of Colorectal Adenoma to Carcinoma,” Cancer Letters, Vol. 205, No. 1, 2004, pp. 97-106.
doi:10.1016/j.canlet.2003.09.033
|
[17]
|
S. Krueger, T. Kalinski, H. Wolf, U. Kellner and A. Roessner, “Interactions between Human Colon Carcinoma Cells, Fibroblasts and Monocytic Cells in Coculture-Regulation of Cathepsin B Expression and Invasiveness,” Cancer Letters, Vol. 223, No. 2, 2005, pp. 313-322.
|
[18]
|
C. Jedeszko and B. F. Sloane, “Cysteine Cathepsins in Human Cancer,” Biological Chemistry, Vol. 385, No. 11, 2004, pp. 1017-1027.
|
[19]
|
M. M. Mohamed and B. F. Sloane, “Cysteine cathepsins: Multifunctional Enzymes in Cancer,” Nature Reviews Cancer, Vol. 6, No. 10, 2006, pp. 764-775.
|
[20]
|
V. Turk, B. Turk and D. Turk, “Lysosomal Cysteine Proteases: Facts and Opportunities,” The EMBO Journal, Vol. 20, No. 17, 2001, pp. 4629-4633.
|
[21]
|
C.-C. Chan, C.-W. Fan, Y.-B. Kuo, Y.-H. Chen, P.-Y. Chang, K.-T. Chen, R.-P. Hung and E.-C. Chan, “Multiple Serological Biomarkers for Colorectal Cancer Detection,” International Journal of Cancer, Vol. 126, No. 7, 2010, pp. 1683-1690.
|
[22]
|
L. Herszenyi, F. Farinati, R. Cardin, G. Istvan, L. D. Molnar, I. Hritz, M. De Paoli, M. Plebani and Z. Tulassay, “Tumor Marker Utility and Prognostic Relevance of Cathepsin B, Cathepsin L, Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor Type-1, CEA and CA 19-9 in Colorectal Cancer,” BMC Cancer, Vol. 8, 2008, p. 194. doi:10.1186/1471-2407-8-194
|
[23]
|
V. Gocheva, W. Zeng, D. Ke, D. Klimstra, T. Reinheckel, C. Peters, D. Hanahan and J. A. Joyce, “Distinct Roles for Cysteine Cathepsin Genes in Multistage Tumorigenesis,” Genes & Development, Vol. 20, No. 5, 2006, pp. 543-556.
|
[24]
|
J. A. Joyce, A. Baruch, K. Chehade, N. Meyer-Morse, E. Giraudo, F. Y. Tsai, D. C. Greenbaum, J. H. Hager, M. Bogyo and D. Hanahan, “Cathepsin cysteine Proteases Are Effectors of Invasive Growth and Angiogenesis during Multistage Tumorigenesis,” Cancer Cell, Vol. 5, No. 5, 2004, pp. 443-453.
|
[25]
|
O. Vasiljeva, T. Reinheckel, C. Peters, D. Turk and V. Turk, B. Turk, “Emerging Roles of Cysteine Cathepsins in Disease and Their Potential as Drug Targets,” Current Pharmaceutical Design, Vol. 1, No. 4, 2007, pp. 387-403.
doi:10.2174/138161207780162962
|
[26]
|
J. A. Joyce, “Therapeutic Targeting of the Tumor Microenvironment,” Cancer Cell, Vol. 7, No. 6, 2005, pp. 513-520.
|
[27]
|
J. S. Rao, “Molecular Mechanisms of Glioma Invasiveness: The Role of Proteases,” Nature Reviews Cancer, Vol. 3, No. 7, 2003, pp. 489-501. doi:10.1038/nrc1121
|
[28]
|
C. S. Gondi, S. S. Lakka, D. H. Dinh, W. C. Olivero, M. Gujrati and J. S. Rao, “RNAi-Mediated Inhibition of Cathepsin B and uPAR Leads to Decreased Cell Invasion, Angiogenesis and Tumor Growth in Gliomas,” Oncogene, Vol. 23, No. 52, pp. 8486-8496.
|
[29]
|
J. A. Foekens, J. Kos, H. A. Peters, M. Krasovec, M. P. Look, N. Cimerman, M. E. Meijer-van Gelder, S. C. Henzen-Logmans, W. L. van Putten and J. G. Klijn, “Prognostic Significance of Cathepsins B and L in Primary Human Breast Cancer,” Clinical Oncology, Vol. 16, No. 3, pp. 1013-1021.
|
[30]
|
L. Herszényi, M. Plebani, P. Carraro, M. De Paoli, G. Roveroni, M. Rugge, R. Cardin, R. Naccarato and F. Farinati, “Role and Behavior of Cathepsin B and Cathepsin L in Gastric Cancer,” Orvosi Hetilap, Vol. 136, No. 25, 1995, pp. 1315-1318.
|
[31]
|
A. Schweiger, I. J. Christensen, H. J. Nielsen, S. Sorensen, N. Brünner and J. Kos, “Serum Cathepsin H as a Potential Prognostic Marker in Patients with Colorectal Cancer,” The International Journal of Biological Markers, Vol. 19, No. 4, 2004, pp. 289-294.
|